This approval marks the first-ever for 2 immuno-oncology agents in cancer treatment.
In a press release published today, Bristol-Myers Squibb (BMS) announced the approval of its combination regimen of 2 immuno-oncology agents, nivolumab (Opdivo) and ipilimumab (Yervoy), for patients with BRAF V600 wild-type metastatic melanoma.
This approval marks the first-ever approval of 2 immuno-oncology agents in cancer treatment. According to the FDA, the approval was based on objective response rate, prolonged duration of response, and improvement in progression free survival—outcomes from the CheckMate-069 trial in 142 treatment-naïve patients with unresectable or metastatic melanoma. The trial showed a statistically significant increase in confirmed objective response rate in 95 patients with melanoma expressing wild-type BRAF treated with the combination (60%; 95% confidence interval (CI), 48-71; P<.001), compared with ipilimumab and placebo (47 patients) (11%; 95% CI, 3-25). Nearly 17% of patients treated with the combination had a complete response, while 43% had a partial response.
A 60% reduction in the risk of progression was observed with the combination treatment compared with ipilimumab alone (Hazard ratio = 0.40; 95% CI: 0.22-0.71; P<.002). Median survival improved by more than 4 months with the combination, 8.9 months compared with 4.7 months seen with the ipilimumab-treated cohort.
The combination was, however, responsible for more serious adverse events (62% vs 39%), adverse reactions leading to permanent discontinuation (43% vs 11%) or dose delay (47% vs 2%), and grade 3 or 4 adverse reactions (69% vs 43%). The most frequent serious adverse reactions in patients receiving the combination were colitis (17%), diarrhea (9%), pyrexia (6%), and pneumonitis (5%). Additional clinically significant immune-mediated adverse reactions included pneumonitis, hepatitis, endocrinopathies, nephritis/renal dysfunction, and rash.
“Today’s approval of the Opdivo + Yervoy Regimen marks another first for our research in Immuno-Oncology and represents our unwavering commitment to continually redefine cancer care, and offer patients new treatment options with the goal of improved outcomes,” said Giovanni Caforio, CEO of BMS.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More